Showing 1216 Results
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
Paying for Patient Care: Understanding the Costs and Benefits Now and Later
A new infographic based on a National Pharmaceutical Council peer-reviewed study explains how gaps between upfront costs and long-term savings of innovative treatments can emerge, why we need to…
National Pharmaceutical Council President Dan Leonard in Specialty Pharmacy Times: How Do We Pay for Medical Innovation?
In this month's Specialty Pharmacy Times, National Pharmaceutical Council President Dan Leonard says it’s time to think differently about how we pay for health care and assess value and benefits.
NPC in Morning Consult: “Why Is Drug Spending So High?” Is the Wrong Question
In a column published in Morning Consult, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains that asking why drug spending is so high assumes that…
National Pharmaceutical Council 2017 Annual Report
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that…
A Focus on Patients, Innovation on Rare Disease Day
February 28 is Rare Disease Day, highlighting both the progress made to date in developing treatments for rare diseases, as well as how much work remains to be done. Nearly one in 10 Americans…
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures
Payer evaluation and coverage of pharmaceuticals and medical procedures may differ independent of their clinical benefit. Therapy access depends on factor other than cost and clinical benefit,…
Coverage Decisions May Drive Potential Health Care System Inefficiency
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
National Pharmaceutical Council in STAT: The (relative) risk in misinterpreting health spending statistics
National Pharmaceutical Council Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, explains in his column in STAT that the absolute numbers tell a different story than the…
Health Care Spending Expected to Increase, According to Latest CMS Figures
National health care spending is expected to increase to $5.7 trillion and comprise nearly 20% of the Gross Domestic Product by 2026, according to the latest statistics reported today by the Centers…